The Clinical Efficacy of Combination Therapy with Alirocumab and Atorvastatin Calcium in the Treatment of Acute Coronary Syndrome and Its Impact on Blood Lipid Levels
Objective:To explore the clinical efficacy and impact on blood lipid levels of patients with acute coronary syndrome(ACS)treated with combination therapy of Alirocumab and Atorvastatin Calcium.Method:A total of 96 ACS patients from June 2022 to September 2023 who were admitted in Leping People's Hospital were selected,and they were randomly divided into the study group(n=48)and the control group(n=48).The control group was treated with Atorvastatin Calcium,while the study group was treated with Alirocumab combined with Atorvastatin Calcium.The clinical efficacy,blood lipid levels,oxidative stress and adverse reactions in both groups were compared.Result:In the total effective rate of treatment,95.83%(46/48)in the study group was higher than 81.25%(39/48)in the control group,the difference was statistically significant(P<0.05).After treatment,the low-density lipoprotein cholesterol(LDL-C),total cholesterol(TC)and triglycerides(TG)levels in both groups were decreased,the high-density lipoprotein cholesterol(HDL-C)levels were increased,in comparision of the control group,the LDL-C,TC,and TG levels in the study group were lower,and the HDL-C level was higher,the differences were statistically significant(P<0.05).After treatment,the malondialdehyde(MDA)levels in both groups were decreased,the superoxide dismutase(SOD)levels were increased,in comparision of the control group,the MDA level in the study group was lower,and the SOD level was higher,the differences were statistically significant(P<0.05).In the incidence of adverse reactions,there was no statistically significant difference in the study group[12.50%(6/48)]and the control group[16.67%(8/48)](P>0.05).Conclusion:Alirocumab and Atorvastatin Calcium in the treatment of ACS can improve clinical efficacy,improve blood lipid levels,alleviate oxidative stress reactions,with high safety.
万方数据
维普
